Mankind Pharma Partners with China for New Insulin Drugs in India

Mankind Pharma recently cemented an exclusive in-licensing and marketing agreement with China’s Chongqing Chenan Biopharmaceutical Co. This strategic move aims to commercialize two critical insulin analogues, Insulin Degludec and Insulin Degludec + Aspart Combination, across India.

This collaboration marks a significant advancement in Mankind Pharma’s overarching strategy. The firm is actively strengthening its footprint within the diabetes care segment by expanding its offerings.

Strategic Expansion in Diabetes Care

The addition of these advanced injectable therapies is poised to enhance Mankind Pharma’s market standing. It specifically targets the evolving needs of patients grappling with diabetes.

• Broadens its portfolio of advanced injectable therapies in the Indian market.
• Enhances Mankind Pharma’s position within the crucial injectable diabetes segment.
• Contributes to a significantly more comprehensive treatment portfolio for patients.
• Reinforces the company’s commitment to addressing the evolving needs of patients in India.

Beyond this specific agreement, Mankind Pharma is widely recognized for its diverse operations. The company is actively engaged in developing, manufacturing, and marketing a broad spectrum of pharmaceutical formulations.

These formulations cater to both acute and chronic therapeutic areas. Furthermore, Mankind Pharma maintains a substantial presence in the consumer healthcare products sector, underscoring its varied market approach.

Ultimately, this partnership underscores Mankind Pharma’s steadfast commitment to patients and market leadership. By expanding its diabetes portfolio, the company aims to deliver a broader spectrum of treatment options to the Indian market, solidifying its strategic direction.